Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Gynecology and Obstetrics, Sahlgrenska University Hospital, Gothenburg, Sweden.
Acta Obstet Gynecol Scand. 2022 Jul;101(7):747-757. doi: 10.1111/aogs.14355. Epub 2022 Apr 11.
Surgical complications after primary or interval debulking surgery in advanced ovarian cancer were investigated and associations with patient characteristics and surgical outcomes were explored.
A population-based cohort study including all women with ovarian cancer, FIGO III-IV, treated with primary or interval debulking surgery, 2013-2017. Patient characteristics, surgical outcomes and complications according to the Clavien-Dindo (CD) classification system ≤30 days postoperatively, were registered. Uni- and multivariable regression analyses were performed with severe complications (CD ≥ III) as endpoint. PFS in relation was analyzed using the Kaplan-Meier method.
The cohort included 384 women, where 304 (79%) were treated with primary and 80 (21%) with interval debulking surgery. Complications CD I-V were registered in 112 (29%) patients and CD ≥ III in 42 (11%). Preoperative albumin was significantly lower in the CD ≥ III cohort compared with CD 0-II (P = 0.018). For every increase per unit in albumin, the risk of complications decreased by a factor of 0.93. There was no significant difference in completed chemotherapy between the cohorts CD 0-II 90.1% and CD ≥ III 83.3% (P = 0.236). In the univariable analysis; albumin <30 g/L, primary debulking surgery, complete cytoreduction and intermediate/high surgical complexity score (SCS) were associated with CD ≥ III. In the following multivariable analysis, only intermediate/high SCS was found to be an independent significant prognostic factor. Low (n = 180) vs intermediate/high SCS (n = 204) showed a median PFS of 17.2 months (95% confidence interval [CI] 15.2-20.7) vs 21.5 months (95% CI 18.2-25.7), respectively, with a significant log-rank; P = 0.038.
Advanced ovarian cancer surgery is associated with complications but no significant difference was seen in completion of adjuvant chemotherapy when severe complications occur. Importantly, our study shows that intermediate/high SCS is an independent prognostic risk factor for complications. Low albumin, residual disease and primary debulking surgery were found to be associated with severe complications. These results may facilitate forming algorithms in the decision-making procedure of surgical treatment protocols.
本研究旨在探讨初次或间隔减瘤术后高级别卵巢癌患者的手术并发症,并探讨其与患者特征和手术结局的关系。
本研究为基于人群的队列研究,纳入了 2013 年至 2017 年期间接受初次或间隔减瘤术治疗的所有国际妇产科联盟(FIGO)分期为 III-IV 期的卵巢癌患者。记录术后 30 天内的患者特征、手术结局和并发症(根据 Clavien-Dindo 分级系统)。采用单变量和多变量回归分析严重并发症(CD≥III 级)为终点。使用 Kaplan-Meier 方法分析无进展生存期(PFS)。
本队列共纳入 384 例患者,其中 304 例(79%)接受初次减瘤术,80 例(21%)接受间隔减瘤术。112 例(29%)患者发生 CD I-V 级并发症,42 例(11%)发生 CD≥III 级并发症。与 CD 0-II 级患者相比,CD≥III 级患者的术前白蛋白显著降低(P=0.018)。白蛋白每增加一个单位,并发症风险降低 0.93 倍。CD 0-II 级和 CD≥III 级患者的化疗完成率分别为 90.1%和 83.3%(P=0.236),差异无统计学意义。单变量分析显示,白蛋白<30g/L、初次减瘤术、完全肿瘤减灭术和中/高手术复杂度评分(SCS)与 CD≥III 级相关。多变量分析显示,仅中/高 SCS 是独立的预后危险因素。低 SCS(n=180)和中/高 SCS(n=204)患者的中位 PFS 分别为 17.2 个月(95%CI 15.2-20.7)和 21.5 个月(95%CI 18.2-25.7),差异具有统计学意义(log-rank 检验,P=0.038)。
高级别卵巢癌手术与并发症相关,但严重并发症发生时,辅助化疗的完成率无显著差异。重要的是,本研究表明,中/高 SCS 是并发症的独立预后危险因素。低白蛋白、残留疾病和初次减瘤术与严重并发症相关。这些结果可能有助于在手术治疗方案的决策过程中制定算法。